Physician profile
John C Reneau
NPI 1437590163
$30,132.41
in general payments reported to CMS, 2019-2025
10 companies · $7,602 in 2025
The $7,602 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $8,416 · 2023: $9,249 · 2024: $4,746 · 2025: $7,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $1,845 · Travel and Lodging: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,661.04 |
| Food and Beverage | $1,845.04 |
| Travel and Lodging | $1,090.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $26,214.57 | 2022-2025 | Beleodaq |
| Kyowa Kirin, INC. | $2,576.35 | 2022-2025 | Poteligeo |
| Adc Therapeutics America, INC. | $802.62 | 2023-2024 | |
| Secura Bio, INC. | $120.71 | 2025 | Copiktra |
| Novartis Pharmaceuticals Corporation | $119.29 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $107.75 | 2023 | Imbruvica |
| Incyte Corporation | $97.20 | 2022 | |
| Seagen INC. | $73.40 | 2022 | |
| Genmab U.S., INC. | $20.52 | 2023 | Epkinly |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Reneau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.